

**May 15, 2024**

**The addition of the following Nine Drugs to the High-Cost Specialty Drug (BIO) Reinsurance coverage.**

AHCCCS is pleased to announce the addition of the following drugs to the High-Cost Specialty Drug Reinsurance effective 02/23/2024:

**Lyfgenia** (lovotibeglogene autotemcel)is a one-time gene therapy approved to treat sickle cell disease for individuals 12 years of age or older who have a history of vaso-occlusive events.

**Casgevy** (exagamglogene autotemcel)is a one-time gene therapy approved to treat sickle cell disease for individuals 12 years and older who have recurrent vaso-occlusive crises and transfusion dependent β-thalassemia.

Due to the formulation of these drugs, there are no rates in the AHCCCS System therefore an Action Request accompanied by the Drug invoice for the actual acquisition cost will need to be submitted to verify MCO Paid amount.

**The following drugs have been added to High-Cost Specialty Drug Reinsurance effective 10/01/2023:**

**Daybue** (trofinetide)is approved to treat Rett syndrome for patients ages 2 years and older.

**Omisirge** (omidubicel-onlv)is a blood-based cell therapy approved to treat hematological malignancies for patients 12 years and older.

**Elevidys** (delandistrogene-moxeparvovec-rokl) is a gene therapy approved to treat ambulatory children aged 4 through 5 years old with Duchenne Muscular Dystrophy (DMD) who have a confirmed mutation in the dystrophin gene.

**Imcrivee** (setmelanotide) is approved for coverage under the AHCCCS program for members 6 years of age and older with obesity and confirmed Bardet Biedl Syndrome.

**The following drugs are to be added to High-Cost Specialty Drug Reinsurance effective 10/01/2024:**

**Prukynd** (mitapivat)is approved to treat hemolytic anemia in adults with pyruvate kinase (PK) deficiency.

**Amtagvi** (lifileucel) is approved to treat unresectable or metastatic melanoma for adults previously treated with a PD-1 blocking antibody, and, if the *BRAF*V600 mutation was positive, a BRAF inhibitor with or without a MEK inhibitor.

**Lenmeldy** (atidarsagene Autotemcel) is approved to treat presymptomatic late infantile (PSLI), presymptomatic early juvenile (PSEJ), or early symptomatic early juvenile (ESEJ)metachromatic leukodystrophy (MLD) in pediatric patients.